Progressive External Ophthalmoplegia

Collin McClelland; Georgios Manousakis; Michael S. Lee

doi:10.1007/s11910-016-0652-7

Progressive External Ophthalmoplegia

Collin McClelland, Georgios Manousakis, Michael S. Lee

Research output: Contribution to journal › Review article › peer-review

67 Scopus citations

Abstract

Progressive external ophthalmoplegia (PEO), marked by progressive bilateral ptosis and diffuse reduction in ocular motility, represents a finding of mitochondrial myopathy rather than a true diagnosis. PEO often occurs with other systemic features of mitochondrial dysfunction that can cause significant morbidity and mortality. Accurate and early recognition of PEO is paramount for the optimal care of these patients. We present an evidence-based review of the presenting neuro-ophthalmic features, differential diagnosis, diagnostic tools, systemic implications, and treatment options for isolated PEO and other PEO-associated mitochondrial syndromes.

Original language	English (US)
Article number	53
Journal	Current neurology and neuroscience reports
Volume	16
Issue number	6
DOIs	https://doi.org/10.1007/s11910-016-0652-7
State	Published - Jun 1 2016

Bibliographical note

Funding Information:
Michael S. Lee has received grants from Eli Lilly, Pfizer, the National Eye Institute, Research to Prevent Blindness, and Quark Pharmaceuticals. Dr. Lee is also the founder and patent holder of Neuro-Ophthalmix.

Funding Information:
This research was supported by the unrestricted grant from the Research to Prevent Blindness (New York, NY).

Publisher Copyright:
© 2016, Springer Science+Business Media New York.

Keywords

Mitochondrial myopathy
Progressive external ophthalmoplegia

Access

10.1007/s11910-016-0652-7

OpenUrl availability

Full text

Cite this

@article{8ecbe85ae26f4beda4c6752b97a43a59,

title = "Progressive External Ophthalmoplegia",

abstract = "Progressive external ophthalmoplegia (PEO), marked by progressive bilateral ptosis and diffuse reduction in ocular motility, represents a finding of mitochondrial myopathy rather than a true diagnosis. PEO often occurs with other systemic features of mitochondrial dysfunction that can cause significant morbidity and mortality. Accurate and early recognition of PEO is paramount for the optimal care of these patients. We present an evidence-based review of the presenting neuro-ophthalmic features, differential diagnosis, diagnostic tools, systemic implications, and treatment options for isolated PEO and other PEO-associated mitochondrial syndromes.",

keywords = "Mitochondrial myopathy, Progressive external ophthalmoplegia",

author = "Collin McClelland and Georgios Manousakis and Lee, {Michael S.}",

note = "Funding Information: Michael S. Lee has received grants from Eli Lilly, Pfizer, the National Eye Institute, Research to Prevent Blindness, and Quark Pharmaceuticals. Dr. Lee is also the founder and patent holder of Neuro-Ophthalmix. Funding Information: This research was supported by the unrestricted grant from the Research to Prevent Blindness (New York, NY). Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = jun,

day = "1",

doi = "10.1007/s11910-016-0652-7",

language = "English (US)",

volume = "16",

journal = "Current neurology and neuroscience reports",

issn = "1528-4042",

publisher = "Current Medicine Group",

number = "6",

}

TY - JOUR

T1 - Progressive External Ophthalmoplegia

AU - McClelland, Collin

AU - Manousakis, Georgios

AU - Lee, Michael S.

N1 - Funding Information: Michael S. Lee has received grants from Eli Lilly, Pfizer, the National Eye Institute, Research to Prevent Blindness, and Quark Pharmaceuticals. Dr. Lee is also the founder and patent holder of Neuro-Ophthalmix. Funding Information: This research was supported by the unrestricted grant from the Research to Prevent Blindness (New York, NY). Publisher Copyright: © 2016, Springer Science+Business Media New York.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Progressive external ophthalmoplegia (PEO), marked by progressive bilateral ptosis and diffuse reduction in ocular motility, represents a finding of mitochondrial myopathy rather than a true diagnosis. PEO often occurs with other systemic features of mitochondrial dysfunction that can cause significant morbidity and mortality. Accurate and early recognition of PEO is paramount for the optimal care of these patients. We present an evidence-based review of the presenting neuro-ophthalmic features, differential diagnosis, diagnostic tools, systemic implications, and treatment options for isolated PEO and other PEO-associated mitochondrial syndromes.

AB - Progressive external ophthalmoplegia (PEO), marked by progressive bilateral ptosis and diffuse reduction in ocular motility, represents a finding of mitochondrial myopathy rather than a true diagnosis. PEO often occurs with other systemic features of mitochondrial dysfunction that can cause significant morbidity and mortality. Accurate and early recognition of PEO is paramount for the optimal care of these patients. We present an evidence-based review of the presenting neuro-ophthalmic features, differential diagnosis, diagnostic tools, systemic implications, and treatment options for isolated PEO and other PEO-associated mitochondrial syndromes.

KW - Mitochondrial myopathy

KW - Progressive external ophthalmoplegia

UR - http://www.scopus.com/inward/record.url?scp=84963568326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963568326&partnerID=8YFLogxK

U2 - 10.1007/s11910-016-0652-7

DO - 10.1007/s11910-016-0652-7

M3 - Review article

C2 - 27072953

AN - SCOPUS:84963568326

SN - 1528-4042

VL - 16

JO - Current neurology and neuroscience reports

JF - Current neurology and neuroscience reports

IS - 6

M1 - 53

ER -

Progressive External Ophthalmoplegia

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this